Travere Therapeutics, Inc. (TVTX) Q3 2025 Earnings Name October 30, 2025 4:30 PM EDT
Firm Contributors
Nivi Nehra – Vice President of Company Communications & Investor Relations
Eric Dube – President, CEO & Director
Jula Inrig – Chief Medical Officer
Peter Heerma – Chief Business Officer
Chris Cline – Chief Monetary Officer
William Rote – Chief Analysis Officer
Convention Name Contributors
Joseph Schwartz – Leerink Companions LLC, Analysis Division
Laura Chico – Wedbush Securities Inc., Analysis Division
Anupam Rama – JPMorgan Chase & Co, Analysis Division
Yigal Nochomovitz – Citigroup Inc. Alternate Analysis
Gavin Clark-Gartner – Evercore ISI Institutional Equities, Analysis Division
Mohit Bansal – Wells Fargo Securities, LLC, Analysis Division
Prakhar Agrawal – Cantor Fitzgerald & Co., Analysis Division
Maurice Raycroft – Jefferies LLC, Analysis Division
Jason Zemansky – BofA Securities, Analysis Division
Alexander Thompson – Stifel, Nicolaus & Firm, Included, Analysis Division
Joseph Pantginis – H.C. Wainwright & Co, LLC, Analysis Division
Presentation
Operator
Good afternoon, and welcome to the Travere Therapeutics’ Third Quarter 2025 Monetary Outcomes Convention Name. Right this moment’s name is being recorded.
Presently, I want to flip the convention name over to Nivi Nehra, Vice President, Company Communications and Investor Relations. Please go forward, Nivi.
Nivi Nehra
Vice President of Company Communications & Investor Relations
Thanks, operator. Good afternoon, and welcome to Travere Therapeutics’ Third Quarter 2025 Monetary Outcomes and Company Replace Name. Thanks, all, for becoming a member of.
Right this moment’s name shall be led by Dr. Eric Dube, our President and Chief Govt Officer. Eric joined within the ready remarks by Dr. Jula Inrig, our Chief Medical Officer; Peter Heerma, our Chief Business Officer; and Chris Cline, our Chief Monetary Officer. Dr. Invoice Rote, our Chief Analysis Officer, will be part of us for the Q&A.
Earlier than we start, I might prefer to remind everybody that statements made throughout this name relating to issues that aren’t historic details are forward-looking
